Subcutaneous Partnerships Are Stepping Stones: Halozyme Touts Its Insulin Product
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite multiple partnerships around a technology platform that can ease administration of existing drugs, Halozyme says its future prospects revolve more around a significant opportunity in insulin-pump products.
You may also be interested in...
Safety Petition Against Baxter’s Immune Globulin HyQvia Could Limit Use
Last-minute petitions traditionally target ANDAs, but this submission raises concerns about a BLA for a product trying to stand out in the relatively undifferentiated immune globulin market.
ViroPharma Talks Cinryze Sales, EU Launches
ViroPharma assures investors that its lead product Cinryze is growing and that launches in the EU are on track during an analyst day presentation.
Subcutaneous Herceptin Meets Goals In Phase III Trial
New subcutaneous formulation of Roche's breast cancer biologic Herceptin is comparable to intravenous version, prompting the companies to file for approval in Europe in 2012. Yet, U.S. filing could take longer.